相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report
Juan Martin-Liberal et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
An Early Pregnancy HbA1c ≥5.9% (41 mmol/mol) Is Optimal for Detecting Diabetes and Identifies Women at Increased Risk of Adverse Pregnancy Outcomes. Diabetes Care 2014;37:2953-2959
Ruth C. E. Hughes et al.
DIABETES CARE (2015)
Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells
Pamela M. Odorizzi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
PD-1 Suppresses Protective Immunity to Streptococcus pneumoniae through a B Cell-Intrinsic Mechanism
Jerome T. McKay et al.
JOURNAL OF IMMUNOLOGY (2015)
Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer
Aaron I. Loochtan et al.
MUSCLE & NERVE (2015)
Tuning of Antigen Sensitivity by T Cell Receptor-Dependent Negative Feedback Controls T Cell Effector Function in Inflamed Tissues
Tetsuya Honda et al.
IMMUNITY (2014)
Gain-of-function STAT1 mutations are associated with PD-L1 overexpression and a defect in B-cell survival
Neil Romberg et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
Taku Okazaki et al.
NATURE IMMUNOLOGY (2013)
Programmed cell death 1 inhibits inflammatory helper T-cell development through controlling the innate immune response
Yuxiang Rui et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
PD-1 Dependent Exhaustion of CD8+ T Cells Drives Chronic Malaria
Joshua M. Horne-Debets et al.
CELL REPORTS (2013)
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
Tadashi Yokosuka et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family
Helene Bour-Jordan et al.
IMMUNOLOGICAL REVIEWS (2011)
CD4 T Cells Promote Rather than Control Tuberculosis in the Absence of PD-1-Mediated Inhibition
Daniel L. Barber et al.
JOURNAL OF IMMUNOLOGY (2011)
IFN-α Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity
Seigo Terawaki et al.
JOURNAL OF IMMUNOLOGY (2011)
T Cells from Programmed Death-1 Deficient Mice Respond Poorly to Mycobacterium tuberculosis Infection
Sultan Tousif et al.
PLOS ONE (2011)
Tumor Cell Expression of Programmed Cell Death-1 Ligand 1 Is a Prognostic Factor for Malignant Melanoma
Ryosuke Hino et al.
CANCER (2010)
PD-1 deficiency results in the development of fatal myocarditis in MRL mice
Jian Wang et al.
INTERNATIONAL IMMUNOLOGY (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis
Eszter Lazar-Molnar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
PD-1-Mediated Suppression of IL-2 Production Induces CD8+ T Cell Anergy In Vivo
Shunsuke Chikuma et al.
JOURNAL OF IMMUNOLOGY (2009)
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal
Brian T. Fife et al.
NATURE IMMUNOLOGY (2009)
Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice
Julie A. Lucas et al.
JOURNAL OF IMMUNOLOGY (2008)
Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers
Juro Nakanishi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy
Fumihiko Tsushima et al.
BLOOD (2007)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Junzo Hamanishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway
Brian T. Fife et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Tissue expression of PD-L1 mediates peripheral T cell tolerance
ME Keir et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Restoring function in exhausted CD8 T cells during chronic viral infection
DL Barber et al.
NATURE (2006)
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance
Changping Wu et al.
ACTA HISTOCHEMICA (2006)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes
J Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
RH Thompson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells
YE Latchman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses
SC Liang et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
PD-1 inhibits antiviral immunity at the effector phase in the liver
YH Iwai et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
TJ Curiel et al.
NATURE MEDICINE (2003)
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells
P Loke et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice
T Okazaki et al.
NATURE MEDICINE (2003)
Expression of programmed death 1 ligands by murine T cells and APC
T Yamazaki et al.
JOURNAL OF IMMUNOLOGY (2002)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine
T Okazaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells
SY Tseng et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
H Nishimura et al.
SCIENCE (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
